Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia

Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia

Objectives This review aims to see the progress of several clinically-used monoclonal antibodies in treating ALL patients and how they improved patients' outcomes.Methods We searched Web of Science, Elsevier and PubMed for relevant published studies, and summarized eligible evidence on the mana...

Full description

Bibliographic Details
Main Authors:	Zheng Shi, Yiqian Zhu, Jing Zhang, Baoan Chen
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-12-01
Series:	Hematology
Subjects:	Acute lymphoblastic leukemia adult monoclonal antibodies blinatumomab ofatumumab Inotuzumab Ozogamicin
Online Access:	https://www.tandfonline.com/doi/10.1080/16078454.2022.2074704

Similar Items

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
by: Nicola Stefano Fracchiolla, et al.
Published: (2023-09-01)

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
by: Bachar Samra, et al.
Published: (2020-06-01)

Very rare near‐haploid acute lymphoblastic leukemia resistant to immunotherapy and CAR‐T therapy in 19‐year‐old male patient
by: Tomas Arpas, et al.
Published: (2022-03-01)

Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia
by: Diego Conde-Royo, et al.
Published: (2020-10-01)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
by: Uy N, et al.
Published: (2018-04-01)

Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
by: Tomoaki Ueda, et al.
Published: (2022-01-01)

Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment
by: David I. Marks, et al.
Published: (2019-10-01)

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
by: Luca Bertamini, et al.
Published: (2018-11-01)

Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
by: Yurkiewicz IR, et al.
Published: (2018-07-01)

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
by: Enrico Maffini, et al.
Published: (2019-05-01)

Novel Immunotherapy Agents for Acute Lymphoblastic Leukaemia
by: David Pesántez, et al.
Published: (2017-08-01)

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
by: Amandeep Aujla, et al.
Published: (2019-04-01)

Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations
by: Jeremy D. Rubinstein, et al.
Published: (2023-08-01)

First case of near haploid philadelphia negative B-Cell acute lymphoblastic leukaemia relapsing as acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
by: Claire Horgan, et al.
Published: (2020-01-01)

Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
by: Warren Fingrut, et al.
Published: (2020-12-01)

Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
by: Franquiz MJ, et al.
Published: (2020-02-01)

Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
by: Sandrine Niyongere, et al.
Published: (2020-06-01)

Successful treatment with blinatumomab for acute lymphoblastic leukemia in an older adult patient complicated with hepatocarcinoma
by: Masuho Saburi, et al.
Published: (2024-01-01)

Targeting CD22 for the Treatment of B-Cell Malignancies
by: Shah NN, et al.
Published: (2021-07-01)

Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date
by: Hathaway L, et al.
Published: (2018-10-01)

Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia
by: Benoît Brethon, et al.
Published: (2021-02-01)

Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia
by: Darshana Jani, et al.
Published: (2018-02-01)

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
by: Elias Jabbour, et al.
Published: (2023-03-01)

Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL
by: Federico Lussana, et al.
Published: (2023-02-01)

A case of leukemia cutis showing annular erythema during the course of Philadelphia chromosome‐positive acute B‐lymphoblastic leukemia
by: Hizuru Tomita, et al.
Published: (2024-02-01)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
by: Le Jeune C, et al.
Published: (2016-02-01)

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy
by: Francesco Paolo Tambaro, et al.
Published: (2020-09-01)

Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study
by: Nicolas Boissel, et al.
Published: (2022-03-01)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
by: Hagop Kantarjian, et al.
Published: (2023-05-01)

Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
by: Masaya Abe, et al.
Published: (2021-01-01)

Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia
by: Katarzyna Pawinska-Wasikowska, et al.
Published: (2022-01-01)

Detection of Myosin 1g Overexpression in Pediatric Leukemia by Novel Monoclonal Antibodies
by: Rosa Isela Rodríguez-Téllez, et al.
Published: (2022-04-01)

Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy
by: Si‐Man Huang, et al.
Published: (2023-12-01)

Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study
by: Hongsheng Zhou, et al.
Published: (2022-12-01)

Negative Impact of Gemtuzumab Ozogamicin on CD33-Positive Early T-Cell Precursor Acute Lymphoblastic Leukemia: A Case Report
by: Osamu Imataki, et al.
Published: (2024-02-01)

Have CD19-directed immunotherapy and haploidentical hematopoietic cell transplantation transformed pediatric B-cell acute lymphoblastic leukemia into a chronic disease?
by: Holly Pariury, et al.
Published: (2021-01-01)

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment
by: Hoda Pourhassan, et al.
Published: (2023-08-01)

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
by: Hagop M. Kantarjian, et al.
Published: (2021-11-01)

Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia in first salvage
by: Jae‐Ho Yoon, et al.
Published: (2019-12-01)

Reduced‐dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B‐cell acute lymphoblastic leukemia
by: Jing Lu, et al.
Published: (2024-03-01)